New Contract Reflects Oncology GPO’s Continued Growth Since January 2005 Launch
FOR IMMEDIATE RELEASE
Contact: Stacie Byars, WeissComm Partners
415-946-1072
sdbyars@wcpglobal.com
South San Francisco, Calif. – July 22, 2008 – Onmark, the leading national group purchasing organization (GPO) for community-based practices and a McKesson Specialty company, has added EMEND® for Injection (fosaprepitant dimeglumine) to its contract portfolio, continuing its commitment to ensure access to the latest specialty drugs at competitive pricing. Developed and marketed by Merck & Co., EMEND is an antiemetic medication that reduces nausea and vomiting for patients receiving chemotherapy.
“The rapid growth in Onmark’s contract portfolio over the past three and a half years reflects our commitment to providing industry-leading value to more than 2,600 member clinics,” said Pat Blake, president of McKesson Specialty.
Onmark serves practices in the community-based treatment setting through its pharmaceutical contract portfolio, which includes brand and generic products that represent the majority of the most widely used chemotherapy, biologic and supportive care agents. In addition, Onmark provides programs and resources designed to help clinics increase efficiencies, lower operating costs and maintain clinical excellence for their patients.
“We are passionate about delivering value to our members through our relationships with leading pharmaceutical and biologics manufacturers,” said Mike Cunningham, PharmD, vice president and general manager of Onmark.
“Through our focus on delivering innovative contracts, practice management resources, clinical tools and educational programs, we enable physicians and their staff to run their practices more efficiently and provide the highest quality patient care possible.”
Members who purchase through Onmark have access to significant discounts and rebate opportunities, as well as the lowest pricing available through McKesson Specialty, one of the largest distributors of products and services to the community physician market. For a listing of all pharmaceutical contracts, services and educational programs available to Onmark members, visit www.onmarkservices.com.
About Onmark
Onmark, a McKesson Specialty company, is the leading national group purchasing organization (GPO) for community-based practices. One of the largest GPOs in the community-based setting, Onmark has more than 2,660 members representing more than 4,400 physicians with over $8 billion in combined annual drug purchasing power. As a part of McKesson Corporation and through its strategic relationships with pharmaceutical companies and industry experts, Onmark provides its members with the lowest pricing available through McKesson Specialty, access to a full portfolio of competitive contracts for pharmaceutical products and medical/surgical supplies, practice management resources, clinical tools and educational programs. For information about the products, services and programs available to Onmark members, visit www.onmarkservices.com.
About McKesson and McKesson Specialty
McKesson Corporation, currently ranked 18th on the Fortune 500, is a healthcare services and information technology company dedicated to helping its customers deliver high-quality healthcare by reducing costs, streamlining processes and improving the quality and safety of patient care. McKesson is the longest-operating company in healthcare today, marking its 175th anniversary this year. Over the course of its history, McKesson has grown by providing pharmaceutical and medical-surgical supply management across the spectrum of care; healthcare information technology for hospitals, physicians, homecare and payors; hospital and retail pharmacy automation; and services for manufacturers and payors designed to improve outcomes for patients. The McKesson Specialty business unit, which includes OTN and Onmark, delivers services that manufacturers, payors and providers need to ensure specialty pharmaceutical products, coordinated reimbursement and clinical services are available to patients with complex diseases. For more information, visit www.mckesson.com.
# # #
|
